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Background. The cost of care for end-stage renal disease
(ESRD) is known to be high. The factors responsible for higher
ESRD cost develop during chronic kidney disease (CKD),
where the data on distribution of cost are limited.
Methods. This retrospective cohort study of 1995 through
1998 incident dialysis patients was performed to study the dis-
tribution of costs during the 24 months prior to initiation of
dialysis. Patient data were obtained from the Centers for Medi-
care and Medicaid Services (CMS). Patients who were Medi-
care eligible for at least 2 years prior to initiation of dialysis were
included in the study. Financial data were obtained from Medi-
care Part A and Part B claims and inflationary adjustments were
made. The study period was divided into four segments based
on overall distribution of cost.
Results. The mean age was 75 years, 51% were males, 73%
were white, and 22% were black. Overall, patient comorbidity
increased significantly during the study years. Cost showed a
sharp increase in the last 6 months prior to initiation of dialysis.
Hospitalization was the major component of cost throughout
study period. Patients who initiated hemodialysis incurred a
higher cost compared to patients who initiated other modes of
kidney replacement therapy. Patients with diabetes or cardio-
vascular disease incurred higher cost compared to those who
had no diabetes or cardiovascular disease, respectively.
Conclusion. These data showed that hospitalization was the
major component of the sharp increase in cost around the ini-
tiation of dialysis. Increased comorbidity was associated with
higher cost. A focus on timely management of CKD may pre-
vent future morbidity and costs.
Health care costs in the United States are extremely
high and are projected to increase further over the next
decade. The National Health Expenditure (NHE) was
13.6% of gross domestic product (GDP) in 1996 and es-
timated to go up to 16.6% by 2007 [1]. In “real” dol-
lars, NHE has increased from $73.2 billion in 1970 to
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$1.04 trillion in 1996 and is expected to double by 2007 [1].
The total cost of care for end-stage renal disease (ESRD)
patients who constitute only 0.5% of the Medicare pop-
ulation [2] was over $15 billion in 1997 and is expected
to increase to $28 billion by 2010 [3]. The main source of
growth in program expenditure appears to be the overall
increase in number of patients with ESRD [3] and accep-
tance of patients with high comorbidity into the program
[4].
As health care expenditure continues to escalate,
health care providers are seeking strategies to constrain
cost, while maintaining better standards of patient care.
The first necessary step to control the growth of the health
care cost is to understand the underlying cause of its
increase. Increasing comorbidity during chronic kidney
disease (CKD) patients [4] may be responsible for rapid
escalation of cost after the initiation of dialysis. The soci-
etal burden of the CKD is increasing and its prevalence
in the United States adult population has been estimated
to be approximately 20 million [5]. This population may
be the ideal target for interventions, aimed at reduction
of morbidity and cost of care after initiation of dialysis.
Two retrospective studies have evaluated costs in CKD
patients in the period before ESRD using managed care
databases [6, 7]. Both studies had design limitations which
calls into question the validity of their results and limits
interpretation. The first study evaluated 1936 incident
dialysis patients from 22 states in the 12-month period
preceding initiation of dialysis [6]. They found mean
costs per patient over the study period of $26,204, $9623,
and $1503 for facility services, professional services, and
outpatient pharmacy, respectively. Unfortunately, inves-
tigators included patients with both acute and chronic
renal failure, did not exclude patients who had insignifi-
cant dialysis, (low charges or low number of dialysis ses-
sions, which would most likely indicate acute renal failure
and not ESRD) in the post-ESRD period and did not cap-
ture postdialysis costs. The second study included 2114
patients from 19 states [7]. These investigators also cap-
tured patients with acute renal failure (36.1%) and 13%
had only one dialysis claim. They only evaluated costs
for 6 months before and 3 months after the first dialysis
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period and calculated costs on charges submitted rather
than allowed charges. Their patient population was not
reflective of the average dialysis population in that they
were quite young (mean age 56 years) and had a very
low percentage of patients with diabetes (less than 20%).
Thus, we sought to evaluate costs in a representative
United States cohort of elderly patients initiating dialy-
sis therapy for CKD during an expanded timeframe both
before and after initiation of dialysis.
Using data from the Center for Medicare and Medi-
caid Services (CMS), we studied the distribution of cost
during the 24 months prior to initiation and 6 months af-
ter initiation of dialysis among a cohort of United States
patients ≥67 years who initiated dialysis between 1995
and 1998.
METHODS
Data
Incident ESRD patient data from 1995 through 1998
were obtained from the CMS. Patients aged 67 years or
older at the time of initiation of dialysis and having Medi-
care as their primary payer, with coverage for both Part A
and Part B services 24 months prior to initiation of dialy-
sis were included. The use of ≥67 years age limit ensured
Medicare eligibility for 24 months prior to initiation of
dialysis. Part A accounts for institutional claims whereas
Part B accounts for physician and supplier claims. To
ensure the availability of complete claims data, patients
enrolled in a Medicare + Choice health maintenance or-
ganization (HMO) or having Medicare as a secondary
payer (MSP) were excluded. Patients who had evidence
of significant dialysis therapy (defined as at least 6 months
of dialysis claims that reached a threshold of $675 per
month [8]) prior to the first service date (FSD) were also
excluded. The initiation of dialysis was identified by using
the FSD of ESRD.
Study period
The study period included 24 months prior to and
6 months after initiation of dialysis. The study months
prior to initiation of dialysis were assigned a negative
symbol and the months after the initiation of dialysis were
assigned a positive symbol. The study period was divided
into four segments: (1) from month –24 to month –6 [pe-
riod I (19 months)], (2) from month –5 to –2 [period II (4
months)], (3) from month –1 to month +2 [period III (3
months)], and (4) from month +3 to month +6 [period
IV (4 months)]. The division of study period was based
on the overall distribution of cost.
Patient characteristics
Patient demographics were obtained from the Renal
Beneficiary and Utilization System (REBUS) while pri-
mary renal diagnosis and laboratory data within 45 days
of initiation of dialysis were obtained from the Medical
Evidence Form. The dialysis modality was established by
using the first recorded modality in the Medical Evidence
Form. However, if the first modality was “unknown dial-
ysis” or nothing was listed, then either (1) “unknown
modality” was recorded if this was the only record in
the first 6 months of ESRD, or (2) if multiple records ex-
isted within the first 6 months, the first listed modality was
recorded. Using the International Classification of Dis-
eases, Ninth Revision, Clinical Modification (ICD-9-CM)
and Physician’s Current Procedural Terminology (CPT)
codes, comorbid conditions were characterized from Part
A and Part B Medicare claims during the 24-month pe-
riod prior to initiation of dialysis. A comorbid condition
was assigned if patient had at least one hospital or skilled
nursing facility claim or two claims (different dates) from
Part B or outpatient Medicare claims files for that partic-
ular condition [9]. Patients were characterized as having
diabetes if they had “diabetes” listed as the primary re-
nal diagnosis or as a comorbid condition on the Medical
Evidence Form or if they had other Medicare claims for
diabetes.
Cost analysis
Financial data for the entire study period were ob-
tained from Medicare Part A and Part B claims. The
Medicare allowable amounts for Part A were the sum
of Medicare payments, patient deductibles, coinsurance,
and amounts paid by other payers for Part A claims.
Medicare allowable amounts for Part B claims were pro-
vided by CMS as a separate variable. Total Medicare al-
lowable per-member-per-month (PMPM) amounts were
calculated by dividing the sum of Medicare allowable
amounts (Part A plus Part B) for all patients by the sum
of the months at risk for all patients. In the case of Medi-
care claims that spanned monthly boundaries, the allow-
able Medicare amount was linearly prorated based on the
claim start (from) and end (through) dates. The average
daily amount was calculated for the entire claim period,
then the dollars were apportioned and assigned to each
month based on the number of days the claim covered
within each month.
Part A Medicare payment categories are broken down
into Part A inpatient, Part A outpatient, and Part
A other. Part A inpatient included medical diagnosis-
related groups (DRGs), surgical DRGs, and other. Part
A outpatient included chronic dialysis services, recom-
binant human erythropoietin (rHuEPO), calcitriol and
intravenous iron administered in the dialysis unit, cost
for laboratory tests, pharmacy, and other charges. Part
A other included Skilled Nursing Facility, Home Health
Agency, and Hospice. Part B Medicare payment cate-
gories included physician and supplier payments, includ-
ing physician payments for surgeries, evaluation, and
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Table 1. Patients ≥67 years of age who initiated dialysis between 1995 and 1998 in the United States
1995 1996 1997 1998 Total P value
Age years 75 ± 6 75 ± 6 75 ± 6 76 ± 6 75 ± 6 <0.05
67–70 % 27 26 24 23 25
71–75 % 32 32 31 30 32
76–80 % 23 23 24 26 24
>80 % 18 19 20 21 20
Female % 50 49 49 50 49
Race
White % 72 71 74 73 73 <0.001
Black % 23 23 22 22 22
Other % 5 6 5 5 5
Primary kidney disease
Diabetes % 36 38 38 40 38 <0.001
Hypertension % 36 35 35 35 35
Glomerulonephritis % 8 8 7 7 7
Interstitial nephritis % 5 5 4 4 5
Other/unknown % 16 14 15 13 15
Laboratory measures
Hematocrit % 28.4 ± 5.3 28.6 ± 5.2 29.3 ± 5.2 29.3 ± 5.2 28.9 ± 5.2
Albumin g/dL 3.3 ± 0.6 3.2 ± 0.7 3.2 ± 0.6 3.2 ± 0.6 3.2 ± 0.6
Glomerular filtration 8.3 ± 8.6 8.4 ± 4.5 8.9 ± 5.8 9.4 ± 9.0 8.8 ± 7.2
rate mL/min/1.73 m2
Dialysis modality
Hemodialysis % 90 91 90 93 91
Peritoneal dialysis % 9 9 8 7 8
Other dialysis % 1 0.8 2 0.4 1
Transplant % 0.1 0.1 0.1 0.1 0.1
management payments (both inpatient and outpatient),
inpatient dialysis, home dialysis, vascular access, some
medications such as rHuEPO, intravenous iron, and im-
munosuppressants that are administered in a physician’s
office, durable medical equipment, and other payments.
Inflation adjustments
Inflationary adjustments were made as cost data
spanned from 1993 through 1998. The year 1997 was cho-
sen as the base year as cost increased from 1993 through
1997, but slightly declined in 1998. Inflation adjustments
were applied on a quarterly basis. Claims were attributed
to a quarter if the start date of the claim fell within the
quarter. The quarterly price indices for the study years
were obtained from the Office of the Actuary at CMS.
The Medicare Hospital Input Price Index was used to
adjust both inpatient and institutional outpatient costs.
The Medicare Skilled Nursing Facility Input Price In-
dex and Home Health Agency Input Price Index were
used to adjust Skilled Nursing Home and Home Health
Agency amounts, respectively. The Medicare Economic
Index was used to adjust Medicare Part B amounts.
RESULTS
A total of 136,090 patients ≥67 years of age initiated
dialysis between January 1, 1995 and December 31, 1998.
Of the total, 26,769 patients were excluded due to lack
of Medicare Part A claims during the 24 months prior to
initiation of dialysis. The lack of Medicare Part A claims
represented health care coverage other than Medicare,
such as HMOs, Medicare risk contract and MSP cover-
age patients where Medicare was not the primary payer.
Thus, 109,321 patients constituted the final study cohort.
There were 24,744, 26,113, 29,211, and 29,253 incident
dialysis patients ≥67 years of age in 1995, 1996, 1997, and
1998, respectively. The distribution of age, gender, and
race among the patients who were excluded were similar
to those in the final study cohort.
Patient characteristics
The mean ± SD age was 75 ± 5.8 years, 49% were
female and 73% were white. The primary cause of kid-
ney disease was diabetes in 38%, hypertension in 35%,
glomerulonephritis in 7%, interstitial nephritis in 5%,
and a variety of other causes in 15% of patients. Table 1
presents patient demographics, primary cause of kidney
disease, laboratory measures, and dialysis modality dur-
ing each study year. Overall, hypertension was present in
82%, congestive heart failure in 65%, ischemic heart dis-
ease in 59%, diabetes in 53%, and peripheral vascular dis-
ease in 41% of patients. The increasing comorbidity was
statistically significant during the study years. The preva-
lence of comorbid conditions during each study year is
presented in Table 2.
Cost variations during the study periods
Total inflation-adjusted costs showed a sharp increase
in the last 6 months prior to initiation of dialysis, peaking
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Table 2. Increasing comorbidity among incident dialysis patients
≥67 years of age between 1995 and 1998 in the United States
Comorbidity 1995 1996 1997 1998 P value
Congestive heart failure % 59.2 60.4 62.3 64.7 <0.001
Ischemic heart disease % 54.8 56.4 58.5 59.8 <0.001
Myocardial infarction % 16.0 17.3 18.7 19.4 <0.001
Cardiac dysrhythmia % 33.1 35.1 37.2 39.8 <0.001
Pericarditis 0.6 0.7 0.8 0.8 <0.005
Peripheral vascular disease % 36.6 38.6 41.2 42.5 <0.001
Cerebrovascular disease, 24.0 26.6 28.5 29.3 <0.001
transient ischemic attack %
Diabetes % 54.9 55.5 56.5 58.9 <0.001
Hypertension % 73.2 75.6 77.6 81.1 <0.001
Chronic obstructive 23.2 24.3 26.7 27.5 <0.001
pulmonary disease %
Cancer % 20.6 21.4 22.4 23.5 <0.001
at initiation of dialysis. Soon after the initiation of dial-
ysis, the cost decreased but remained at a much higher
level than the cost prior to initiation of dialysis (Fig. 1).
Compared to 1995, the adjusted cost during study pe-
riod I (–24 to –6 months) increased significantly in 1996
(7%), 1997 (14%), and 1998 (14%). A similar trend was
seen within study period II (–5 to –2 months) where cost
increased in 1996 (5%), 1997 (10%), and 1998 (9%), com-
pared to 1995. Although the cost during study period III
(–1 to +1 months) and study period IV (+2 to +6 months)
increased in 1996 (2% and 3%, respectively) and 1997
(4% and 2%, respectively) when compared to the cost
during similar periods in 1995, in 1998 it remained un-
changed during the study period III (–1 to +1 months)
and decreased by 2% during the study period IV (+2 and
+6 months) (data not shown).
Cost components
The distribution of cost among inpatient, outpatient,
other Part A and Part B Medicare claims over the en-
tire study period is shown in Figure 2A. The Medicare
allowable amounts for Part A inpatient was the major
component of the total cost throughout the study period,
followed by Medicare allowable amounts for Part B.
Overall, patients who initiated hemodialysis incurred a
higher cost during all study periods compared to patients
who initiated peritoneal dialysis or other modes of dial-
ysis (Table 3). Patients who received a kidney transplant
had higher costs only during study period III, otherwise
their costs were less than other forms of kidney replace-
ment therapy (Table 3). During all study periods, patients
with diabetes incurred higher cost when compared to
patients who had no diabetes. Similarly, patients with car-
diovascular disease incurred higher cost compared to pa-
tients who had no cardiovascular disease. When patients
with both diabetes and cardiovascular disease were com-
pared to patients with neither diabetes nor cardiovascu-
lar disease, the cost differences during all study periods
were higher (Table 3). The distribution of the cost among
various components during the entire study period for
patients who had neither diabetes nor cardiovascular
disease is shown in Figure 2B, and patients who had both
diabetes and cardiovascular disease is shown in Figure 2C.
Overall higher cost and proportionately higher inpatient
cost during all study periods were seen among patients
with both diabetes and cardiovascular disease as com-
pared to patients who had neither diabetes or cardiovas-
cular disease. A closer view of the distribution of cost
around the initiation of dialysis is presented in Figure 3.
Hospitalization was the single most important cause for
the increase in cost around the time of initiation of
dialysis.
DISCUSSION
The patterns and drivers of ESRD cost have been well
established [abstract; Arora P, et al, J Am Soc Nephrol
10:153A, 1999] [10, 11]. However, the costs during the
pre-ESRD period and the period around the initiation
of dialysis have not been well characterized. This study
provides a comprehensive view of these issues in a large
cohort of Medicare-eligible patients, who initiated dialy-
sis between 1995 and 1998. Our analysis showed that cost
began to increase in the last 6 months before initiation
of dialysis, reached a peak in the first month of dialysis,
and then reached a plateau by the sixth month of dialysis.
The plateau effect can be explained in two ways. First,
most dialysis-related services and supplies are furnished
in exchange for a composite rate, which limits cost fluctua-
tions per patient. Second, mortality rate is extremely high
during the first six months of dialysis (data not shown).
Patients who die are more expensive prior to death, but
after death they do not contribute to cost. The health-
iest patients remain, which will tend to level out costs.
Hospitalizations were the single most important cause of
increased cost around initiation of dialysis. About 69%
of our patient population was in the hospital on their
ESRD initiation date (data not shown). The common
practice of initiating dialysis in a hospital setting might
be one factor that increases costs around the start of dial-
ysis. Patients who initiated hemodialysis had higher cost
compared to patients who initiated peritoneal dialysis or
other renal replacement modalities. Patients who had di-
abetes or cardiovascular disease had a higher cost during
all study periods of CKD when compared to patients who
had no diabetes or cardiovascular disease, respectively.
Nissenson et al [12] also showed that the average charge
for CKD patients enrolled in a HMO increased with age,
increasing serum creatinine, the presence of diabetes or
hypertension. Death within first 6 months of starting dial-
ysis was associated with higher cost before, around, and
after initiation of dialysis. An overall increase in the num-
ber of comorbid conditions among patients accepted for
the ESRD program was observed between 1995 and 1998.
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Fig. 1. Overall distribution of per member
per month (PMPM) Medicare-allowable cost
(1995 through 1998) among Medicare patients
≥67 years of age with chronic kidney disease
in the United States. Month –1 denotes the
month prior to initiation of dialysis, month +1
denotes the month immediately after initia-
tion of dialysis. Cost is adjusted for inflation,
using 1997 as the base year.
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Fig. 2. Overall distribution of per member
per month (PMPM) Medicare-allowable cost
(1995 through 1998), and variation in cost
components among Medicare patients ≥67
years of age. (A) Chronic kidney disease. (B)
Chronic kidney disease and neither diabetes
or cardiovascular disease. (C) Chronic kidney
disease with both diabetes and cardiovascular
disease, in the United States. Month –1 de-
notes the month prior to initiation of dialysis,
month +1 denotes the month immediately af-
ter initiation of dialysis.
While the total adjusted cost of care during the pre-ESRD
period increased between 1995 and 1998, the cost around
the initiation of dialysis and in the first 6 months of dial-
ysis actually stayed about the same or even decreased in
the most recent years.
In our analysis, hospitalizations were the major driver
of cost during the period immediately before and after ini-
tiation of dialysis. A substantial proportion of the ESRD
costs in general (41%) have been attributed to hospital-
izations [13]. The results of our study showing higher cost
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Table 3. Distribution of per member per month cost among various categories of patients ≥67 years of age who initiated dialysis between 1995
and 1998 in the United States
1995–1998 Combined incident patient cohort
Time interval months (−24 to −6) (−5 to −2) (−1 to +2) (+3 to +6)
Number Cost ± SD Cost ± SD Cost ± SD Cost ± SD
Dialysis Modality
Hemodialysis 99376 $993 ± 1342 $1942 ± 3093 $9726 ± 7292 $6224 ± 5578
Peritoneal dialysis 8613 $843 ± 1154 $1591 ± 2599 $7251 ± 5777 $4644 ± 4517
Other/unknown 1242 $782 ± 1186 $2154 ± 5183 $7563 ± 10309 $2732 ± 4545
Transplant 90 $558 ± 697 $1282 ± 4438 $12547 ± 11404 $2718 ± 3521
Comorbidity
Diabetes 61788 $1179 ± 1486 $2119 ± 3229 $9638 ± 7174 $6358 ± 5623
No diabetes 47533 $718 ± 1029 $1652 ± 2882 $9347 ± 7360 $5667 ± 5346
Cardiovascular disease 91849 $1108 ± 1393 $2164 ± 3256 $10083 ± 7361 $6373 ± 5682
No cardiovascular disease 17472 $301 ± 521 $612 ± 1432 $6534 ± 5846 $4547 ± 4320
Cardiovascular disease and diabetes 54646 $1291 ± 1534 $2311 ± 3336 $10091 ± 7245 $6614 ± 5743
No cardiovascular disease and no diabetes 10330 $281 ± 518 $586 ± 1281 $6762 ± 6053 $4538 ± 4341
Outcome at 6 monthsa
Survived 84939 $932 ± 1235 $1740 ± 2792 $8610 ± 6578 $5489 ± 4398
Died 24382 $1140 ± 1596 $2529 ± 3902 $12990 ± 8580 $13021 ± 10632
aPatients who survived or died during the first 6 months after initiation of dialysis.
Month
$
$2,000
$4,000
$6,000
$8,000
$10,000
$12,000
$14,000
$16,000
PM
PM
, a
llo
wa
bl
e 
am
ou
nt
Part B
Other part A
Outpatient
Inpatient
$3,237.87
$813.90
$1,641.77
$1,562.92
$936.31
$2,212.70
$3,370.02
$9,288.91
$373.83
$382.56
$1,306.51
$3,434.42
–1 1 2
Fig. 3. Overall distribution of per member per month (PMPM)
Medicare-allowable cost (1995 through 1998), and variation in cost com-
ponents among Medicare patients ≥67 years of age with chronic kidney
disease immediately 1 month prior and 2 months after initiation of dial-
ysis (a magnified view of cost components).
due to hospitalizations during months immediately after
initiation of dialysis concurred with the previous finding
of higher hospital utilization among dialysis patients at
New England Medical Center [14]. Higher hospitaliza-
tion rate among CKD patients that have higher levels of
serum creatinine, are older, and have cardiac disease prior
to initiation of dialysis has also been previously shown
[15, 16]. An analysis of a managed care database of 1936
incident dialysis patients during the 12 months prior to
initiation of dialysis showed that 62% of the patients were
hospitalized and average cost per admission was $14,818
[6]. We have shown that when adjusted for patient de-
mographics and comorbid conditions, late referral to the
nephrologist and use of temporary vascular access for the
first dialysis were modifiable factors independently asso-
ciated with a higher risk of hospitalizations particularly in
the first few months of initiation of dialysis [14]. We have
also shown that advanced age, cardiovascular illness, and
anemia were independent predictors of hospitalizations
prior to initiation of dialysis [16]. Unfortunately, despite
the presence of potentially modifiable factors that lead to
increased resource utilization, the appropriate manage-
ment for advanced CKD and associated comorbid con-
ditions is not routinely administered [6, 17].
Using a similar cohort, we have recently shown that
placement of dialysis access around the initiation of dial-
ysis was the major cause for hospitalizations among pa-
tients in later stages of CKD [18]. Several studies have
shown an association between late referral to a nephrol-
ogist and lack of a permanent access before dialysis was
initiated [17]. The cost and morbidity related to tempo-
rary vascular access is potentially preventable with op-
timal nephrology care prior to initiation of dialysis. In
1997 the National Kidney Foundation–Kidney Disease
Outcomes Quality Initiative (NKF-K/DOQI) guidelines
recommended that patients with CKD be referred for
construction of an autogenous arteriovenous (AV) fis-
tula when the creatinine clearance is <25 mL/min and
serum creatinine is >4 mg/dL, or within 1 year of an-
ticipated need of chronic hemodialysis [19]. However, in
the United States, the majority of patients begin chronic
hemodialysis without a permanent functional access, and
synthetic grafts are more commonly placed than AV fis-
tulas [20]. In a random sample of 1805 United States adult
patients enrolled in Wave 2 of the Dialysis Morbidity and
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Mortality Study (DMMS), 66% began in-center chronic
hemodialysis with a catheter, 12% with an AV fistula, and
22% with a polytetrafluoroethylene (PTFE) graft. Sur-
prisingly, 2 months after the start of hemodialysis, 32%
of patients were still using a catheter as their primary
access, 19% an AV fistula, and 49% a PFTE graft [21].
These results are in sharp contrast with the prevalence
of AV fistula use in Europe. Investigators of the Dialy-
sis Outcomes and Practice Patterns Study (DOPPS) have
recently reported that 66% of European patients begin
chronic hemodialysis with a functional AV fistula com-
pared with only 15% in the United States [22]. Currently,
Medicare reimburses less for placement of an AV fistula
as compared to a synthetic graft. As the lack of perma-
nent vascular access is not only associated with higher
cost and morbidity, but also with higher mortality among
patients receiving hemodialysis [23], an urgent modifica-
tion in practice patterns and a review of Medicare reim-
bursement policy for vascular access is needed to prevent
avoidable mortality, morbidity, and cost of care.
Overall, cost during the four study periods was higher
among patients who initiated hemodialysis as compared
with patients who initiated other modes of dialysis or
those who received a kidney transplant (with the ex-
ception of period III). The most likely explanation for
the higher cost prior to initiation of dialysis among
hemodialysis patients was the older age and presence
of higher comorbidity. An analysis of a national random
sample of 4025 patients, who were enrolled in the DMMS
Wave 2 study, showed that the selection of peritoneal
dialysis as the treatment modality over hemodialysis was
significantly associated with younger age, white race,
and fewer comorbid conditions. In addition, the use of
peritoneal dialysis was higher among patients who were
employed, married, and living with someone before the
initiation of dialysis and in those who were more au-
tonomous and better educated [24]. A detailed char-
acterization of the case-mix differences between 279
peritoneal dialysis patients and 759 hemodialysis pa-
tients at the onset of dialysis therapy using the Index
of Coexistent Diseases (ICED), showed that the num-
ber and severity of comorbid conditions at the onset of
ESRD was significantly lower among patients who initi-
ated peritoneal dialysis [25]. Available data indicate that
peritoneal dialysis offers some advantages for the increas-
ing number of elderly patients with ESRD, such as hemo-
dynamic stability, steady-state metabolic control, good
control of hypertension, independence from hospital vis-
its, and avoidance of the need for repeated vascular ac-
cess [26]. Thus, in addition to preventing the progression
of comorbid conditions, nephrology care during earlier
CKD may allow the patients to make informed choices
for dialysis modality resulting in cost reduction.
The links between CKD and cardiovascular disease
have long been established by many epidemiologic
studies [27–30]. Patients with CKD are considered in the
highest risk group for cardiovascular disease [31]. In our
analysis cardiovascular disease was a major disease bur-
den. Its importance was suggested by persistently higher
cost during all study periods among CKD patients with
cardiovascular disease. The United States Renal Data
System has recently reported on causes of hospitaliza-
tion over the 2-year period before dialysis initiation. The
cumulative percentage of patients hospitalized for con-
gestive heart failure and ischemic heart disease increased
steadily over those 2 years, an indication of increasing co-
morbidities [4]. Thus, all measures to treat the causes and
factors associated with the development and progression
of cardiovascular disease are warranted. Anemia, a com-
plication of CKD, has been significantly associated with
progression of cardiovascular disease in CKD patients
[30, 32]. The use of rHuEPO and the consistent treatment
of anemia with rHuEPO prior to initiation of dialysis have
been associated with increased survival after initiation of
dialysis [33, 34]. This apparent survival benefit could be
a marker of early intervention or better quality of care.
Although the availability of rHuEPO has revolutionized
the treatment of anemia among dialysis patients, the man-
agement of anemia among CKD patients prior to initia-
tion of dialysis remains suboptimal. From 1995 to 2000,
the overall mean hemoglobin level at dialysis initiation
in the United States has risen from 9.3 to 10 g/dL, but
is still much lower than the K/DOQI target range of 11
to 12 g/dL [4]. Rates of pre-ESRD rHuEPO use in 2000
were only 30% [4]. The significant presence of untreated
anemia, diabetes, dyslipidemias, hypertension, and other
cardiovascular risk factors among patients with earlier
CKD [17] is a call for optimization of practice patterns.
Earlier CKD management for cardiovascular risk factors
and comorbid conditions, such as diabetes and cardio-
vascular disease, may improve the long-term clinical and
economic outcomes.
A wide variety of comorbid conditions which develop
during the course of CKD leads to higher mortality
[35–37] and higher cost of care [38, 39] among ESRD
patients. During the course of our study there was a sig-
nificant increase in comorbid conditions among patients
who were accepted in to the ESRD program. Diabetes
mellitus imposes a great burden on health care costs due
to its growing prevalence and high associated comorbid-
ity. Overall, 53% of our patients were diabetics and in-
curred higher cost throughout the study period compared
to patient who had no diabetes. Patients who died within
6 months of initiation of dialysis had higher costs before,
during, and after initiation of dialysis. This relationship
could be representative of higher number and severity of
comorbidity among patients who died within 6 months of
initiation of dialysis. If the comorbidity among patients
accepted for the ESRD program continues to increase,
the impact on the future cost of the ESRD program can
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be substantial and may require a reevaluation of the cur-
rent Medicare payment system.
Although cost during the pre-ESRD period increased
between 1995 and 1998, cost around initiation of dial-
ysis stayed about the same or even decreased in recent
years. This trend could reflect the fact that dialysis service
payments are covered under a composite rate and pay-
ments have not kept up with increasing inflation. Addi-
tionally, as hospitalizations account for a significant cost,
one may hypothesize that this change in cost behavior
reflects the recent trends in decreased hospitalizations
or length of stay among patients with other chronic dis-
eases [40–42]. Another possibility is that the increased
awareness of the importance of pre-ESRD care during
the mid 1990s led to an increase in pre-ESRD cost but
a decline in cost during ESRD. This would support the
central hypothesis that optimization of pre-ESRD care
is the key to improved clinical and economic outcomes
during ESRD. Further studies are needed to confirm this
possibility.
The results of this study must be interpreted with its
limitations in mind. The inclusion criteria limiting entry to
patients aged ≥67 years limits the generalizability of the
study. The distribution of cost may differ in a younger co-
hort. However, given the overall increase in average age
of the patients initiating dialysis, our results can be gen-
eralized at least to the Medicare population with CKD.
Although there are no published data that directly com-
pare costs of Medicare patients with CKD with Medicare
patients in general, the United States Renal Data Sys-
tem recently published some data using a 5% Medicare
sample that may shed some light on this issue [43]. The
authors present life-table estimates of the probability of
acquiring diagnosis codes for cardiovascular disease and
congestive heart failure in patients 67 years and older
with CKD and no CKD, the same age criteria that was
used in our study. Their analysis shows that patients with
CKD had a higher probability of developing cardiovas-
cular disease and congestive heart failure over a 1-year
follow-up than patients without CKD. Hospitalization
rate was also higher in CKD versus non-CKD patients.
Cost follows increased hospitalization and cormorbidity.
Thus, although direct comparative cost analyses have not
been done, clearly the elderly patient with CKD will be
more costly, in general, than an elderly Medicare patient
without CKD.
In addition, the distribution of cost during earlier CKD
might be different if health care is provided by medical
insurance other than the Medicare. The Medicare risk
(Medicare + Choice) HMO population was over 29,000
in 2001 (6%) [2]. The age distribution of Medicare risk
patients is heavily skewed toward the elderly, reflecting
requirements that only those previously enrolled in a
Medicare + Choice program or managed care pro-
gram could enter Medicare risk programs after initiating
ESRD. This factor would suggest that the elderly patient
population that we evaluated in this study may be similar
in age to Medicare risk patients. Patients with insurance
through Medicaid only, the Department of Veterans Ad-
ministration as well as employer group health plans are
typically younger than Medicare patients [4]. As com-
plete claims data are not available on any of these patients
in the CMS database, it is unclear if these patients have
the same level of comorbidities and cost as Medicare fee-
for-service patients. However, based on data from a study
of younger CKD patients in a managed care setting, the
pattern of costs prior to, around dialysis initiation, and
postdialysis should be similar [7].
Our study population also had a lower prevalence of
diabetes as an ESRD cause than does the general ESRD
population. Patients with diabetes, CKD and that are 65+
years in the general Medicare population have a higher
probability of death than ESRD, compared with younger
patients with diabetes and CKD. Thus, a relatively smaller
percentage of elderly patients with diabetes reach ESRD
[4]. Patients who died in the pre-ESRD period were not
included in this study and their costs (which are pre-
sumably higher) have not been factored in. As we have
demonstrated that costs in diabetic patients with CKD
who go onto ESRD are typically higher in each time
period preceding up to and after initiation of dialysis,
one could presume that this might lead to lower costs in
our study population versus a comparable age group with
more diabetes.
CONCLUSION
We ascertained that the CKD costs peak in the months
immediately before and after initiation of dialysis. The in-
crease in hospitalizations accounted for a sharp increase
in cost before, around, and after initiation of dialysis. Cur-
rently, there is a paucity of data available in the CKD
population that support the concept that managing pa-
tients at an earlier stage of CKD (spending health care
dollars upfront) will reduce future health care expendi-
tures with similar or better health outcomes. Although
yet to be proven in a prospective clinical trial, early diag-
nosis of CKD and timely interventions for complications
of CKD may prevent avoidable morbidity and cost.
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